Sivraj Muralikrishnan

A pragmatic, single-arm clinical trial of a dose modification algorithm for preventing cytopenia-related delays during FOLFOX chemotherapy

Heather M. N. Wright, Tor Devin Tosteson, Kathryn Cunningham Hourdequin, Gregory H. Ripple et autres

us (code pays fourni par la source)

Genetic characteristics and clinical outcomes of driver mutant oligometastatic non small cell lung cancer treated with combination definitive chemoradiotherapy and targeted systemic therapy.

Matthew Pierre Deek, Eshan U. Patel, Benjamin D. Medina, Ioannis Kontopidis et autres

e20676 Background: Treatment of oligometastatic non-small cell lung cancer (omNSCLC) is evolving with increasing use of local therapies to consolidate disease. Our molecular understanding is also improving with better ability to target genetically identified driver mutations. In non-metastatic NSCLC, combined approaches of …

us (code pays fourni par la source)

A pragmatic, single-arm clinical trial of a dose-adjustment algorithm for preventing cytopenia-related delays during FOLFOX chemotherapy.

Gabriel A. Brooks, Heather M. N. Wright, Gregory H. Ripple, Manik A. Amin et autres

6608 Background: Unplanned delays are common during FOLFOX chemotherapy, and cytopenias (neutropenia and/or thrombocytopenia) are the most common cause of delays. We evaluated a novel, provider-driven FOLFOX dose-adjustment algorithm designed to reduce unplanned delays while maintaining chemotherapy dose intensity. Methods: We conducted …

us (code pays fourni par la source)

Data from Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice

Lindsey Elizabeth Roeker, Christopher Paul Fox, Toby Andrew Eyre, Danielle M. Brander et autres

AbstractPurpose: Clinical trials of venetoclax reported negligible rates of clinical tumor lysis syndrome (TLS) in patients with chronic lymphocytic leukemia (CLL) when using an extended dose escalation schedule. We aimed to understand TLS prophylaxis, rates of select adverse events (AE), and impact …

Supplementary Data from Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice

Lindsey Elizabeth Roeker, Christopher Paul Fox, Toby Andrew Eyre, Danielle M. Brander et autres

Supplemental Figure 1.

Supplementary Data from Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice

Lindsey Elizabeth Roeker, Christopher Paul Fox, Toby Andrew Eyre, Danielle M. Brander et autres

Supplemental Table 1 and Supplemental Figure Legends

Data from Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice

Lindsey Elizabeth Roeker, Christopher Paul Fox, Toby Andrew Eyre, Danielle M. Brander et autres

AbstractPurpose: Clinical trials of venetoclax reported negligible rates of clinical tumor lysis syndrome (TLS) in patients with chronic lymphocytic leukemia (CLL) when using an extended dose escalation schedule. We aimed to understand TLS prophylaxis, rates of select adverse events (AE), and impact …

Supplementary Data from Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice

Lindsey Elizabeth Roeker, Christopher Paul Fox, Toby Andrew Eyre, Danielle M. Brander et autres

Supplemental Figure 1.

Supplementary Data from Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice

Lindsey Elizabeth Roeker, Christopher Paul Fox, Toby Andrew Eyre, Danielle M. Brander et autres

Supplemental Table 1 and Supplemental Figure Legends

Comparison of Oncologist and Model Estimates of Risk for Hospitalization During Systemic Therapy for Advanced Cancer

Lukas P. Emery, Sivraj Muralikrishnan, Deborah Schrag, Anna N.A. Tosteson et autres

PURPOSE: A validated risk model with inputs of pretreatment sodium and albumin can identify patients at risk for hospitalization during cancer treatment. We evaluated how the model compares with risk estimates from treating oncologists. METHODS: We evaluated the 30-day risk of hospitalization …

us (code pays fourni par la source)

499 A Retrospective Audit on Detection Rate of Clinically Significant Cancer Among MP-MRI Targeted Biopsy – A Single Centre Experience

E T Zuling, Sivraj Muralikrishnan

Abstract Men with high serum prostate specific antigen (PSA) typically undergo standard transrectal ultrasound-guided prostate biopsy (TRUS-biopsy) during which 10 to 12 cores are obtained. TRUS-biopsy can cause side-effects including bleeding, pain, and infection. Multi-parametric MRI (MP-MRI) used as a triage test …

gb (code pays fourni par la source)

Comparison of clinician and model estimates of risk for hospitalization during systemic therapy for advanced cancer.

Lukas P. Emery, Sivraj Muralikrishnan, Anna N.A. Tosteson, Deborah Schrag et autres

1530 Background: Patients receiving treatment for advanced cancer are at substantial risk for unplanned hospitalization. A validated two-variable risk model can identify patients at increased risk for hospitalization. However, little is known about how model-based estimates of hospitalization risk compare with assessments …

us (code pays fourni par la source)